Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Study Using the ShiraTronics Migraine Therapy System

A Pilot Study Assessing Preliminary Safety and Efficacy of The ShiraTronics Migraine Therapy System in Relieving, Interrupting, and Preventing Chronic Migraine

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this pilot study is to assess the preliminary safety and efficacy of the ShiraTronics Migraine Therapy System in prophylactic treatment of patients with refractory chronic migraine.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Participants who are 22 years of age or older. 2. History of migraine ≥ 12 months. 3. Participants experiencing between 15 to 26 headache days per month, with at least 8 headache days (per month) with migraine phenotype presentation. 4. Inadequate response to, unwilling, or contraindicated to Onabotulinumtoxin A and CGRP monoclonal antibodies therapy. 5. Stable use of migraine medication. Who Should NOT Join This Trial: 1. Post-traumatic headache. 2. Medication overuse headache. 3. New daily persistent headache. 4. Report experiencing unremitting, continuous headaches with no relief. 5. Previously implanted neurostimulator to treat headache. 6. History of cervical radiofrequency ablation or had any other intervention/device for migraine. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Participants who are 22 years of age or older. 2. History of migraine ≥ 12 months. 3. Participants experiencing between 15 to 26 headache days per month, with at least 8 headache days (per month) with migraine phenotype presentation. 4. Inadequate response to, unwilling, or contraindicated to Onabotulinumtoxin A and CGRP monoclonal antibodies therapy. 5. Stable use of migraine medication. Exclusion Criteria: 1. Post-traumatic headache. 2. Medication overuse headache. 3. New daily persistent headache. 4. Report experiencing unremitting, continuous headaches with no relief. 5. Previously implanted neurostimulator to treat headache. 6. History of cervical radiofrequency ablation or had any other intervention/device for migraine.

Treatments Being Tested

DEVICE

neurostimulator

The ShiraTronics Migraine Therapy System

Locations (4)

Genesis Research Services
Broadmeadow, New South Wales, Australia
Australian Medical Research
Hurstville, New South Wales, Australia
CerCare
Wayville, South Australia, Australia
Paincare Perth
Perth, Western Australia, Australia